PB 40 of 2022
National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 4)
I, Caroline Turnour, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following determination.
Dated 28 April 2022
CAROLINE TURNOUR
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) 2
1 Name
This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 4).
This instrument may also be cited as PB 40 of 2022.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 May 2022. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 85AB(1) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)
1 Schedule 1, after item dealing with Anakinra
insert:
Apalutamide
2 Schedule 1, after item dealing with Eletriptan
insert:
Elotuzumab
3 Schedule 1, after item dealing with Olsalazine
insert:
Onasemnogene abeparvovec
4 Schedule 1, after item dealing with Ruxolitinib
insert:
Sacituzumab govitecan